The impact of S- and G2-checkpoint response on the fidelity of G1-arrest by cisplatin and its comparison to a non-cross-resistant platinum(IV) analog

Gynecologic Oncology

Volumn 122, Issue 2, 2011, Pages 402-409

  He, Guangan ^a   Kuang, Jian ^a   Khokhar, Abdul R ^a   Siddik, Zahid H ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Cdk activity; Cell cycle arrest; Checkpoint response; Cisplatin; DNA damage

Indexed keywords

ANTINEOPLASTIC AGENT; CELL DNA; CHECKPOINT KINASE 1; CHECKPOINT KINASE 2; CISPLATIN; CYCLIN B; CYCLIN D1; CYCLIN DEPENDENT KINASE 1; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN E; DIAMINOCYCLOHEXANE(TRANS DIACETATO)(DICHLORO)PLATINUM; HIGH MOBILITY GROUP B1 PROTEIN; HIGH MOBILITY GROUP B2 PROTEIN; NOCODAZOLE; PLATINUM DERIVATIVE; PROTEIN P53; PROTEIN TYROSINE PHOSPHATASE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CELL STRAIN HCT116; COMPLEX FORMATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA DAMAGE; DRUG EXPOSURE; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; INTRACELLULAR SIGNALING; OVARY CANCER; PRIORITY JOURNAL; PROTEIN DNA INTERACTION; PROTEIN PHOSPHORYLATION;

ANTINEOPLASTIC AGENTS; CELL CYCLE; CISPLATIN; CYCLIN-DEPENDENT KINASE 2; CYCLIN-DEPENDENT KINASE 4; DNA DAMAGE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; G1 PHASE; G2 PHASE; HCT116 CELLS; HUMANS; NOCODAZOLE; PHOSPHORYLATION; PROTEIN KINASES; S PHASE;

EID: 79960459554     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2011.04.034     Document Type: Article

References (50)

1. A. Eastman Cell cycle checkpoints and their impact on anticancer therapeutic strategies J Cell Biochem 91 2004 223 231
2. T. Samuel, H.O. Weber, and J.O. Funk Linking DNA damage to cell cycle checkpoints Cell Cycle 1 2002 162 168
3. A.M. Ferguson, L.S. White, P.J. Donovan, and H. Piwnica-Worms Normal cell cycle and checkpoint responses in mice and cells lacking Cdc25B and Cdc25C protein phosphatases Mol Cell Biol 25 2005 2853 2860 (Pubitemid 40381646)
4. G.K. Schwartz Development of cell cycle active drugs for the treatment of gastrointestinal cancers: a new approach to cancer therapy J Clin Oncol 23 2005 4499 4508 (Pubitemid 46196579)
5. A. Eastman, E.A. Kohn, M.K. Brown, J. Rathman, M. Livingstone, D.H. Blank, and G.W. Gribble A novel indolocarbazole, ICP-1, abrogates DNA damage-induced cell cycle arrest and enhances cytotoxicity: similarities and differences to the cell cycle checkpoint abrogator UCN-01 Mol Cancer Ther 1 2002 1067 1078
6. A. Vekris, D. Meynard, M.C. Haaz, M. Bayssas, J. Bonnet, and J. Robert Molecular determinants of the cytotoxicity of platinum compounds: the contribution of in silico research Cancer Res 64 2004 356 362 (Pubitemid 38114118)
7. G.S. Hagopian, G.B. Mills, A.R. Khokhar, R.C. Bast Jr., and Z.H. Siddik Expression of p53 in cisplatin-resistant ovarian cancer cell lines: modulation with the novel platinum analogue (1R, 2R-diaminocyclohexane)(trans-diacetato) (dichloro)-platinum(IV) Clin Cancer Res 5 1999 655 663 (Pubitemid 29131977)
8. K. Mujoo, M. Watanabe, J. Nakamura, A.R. Khokhar, and Z.H. Siddik Status of p53 phosphorylation and function in sensitive and resistant human cancer models exposed to platinum-based DNA damaging agents J Cancer Res Clin Oncol 129 2003 709 718 (Pubitemid 38002302)
9. J. Kuang, G. He, Z. Huang, A.R. Khokhar, and Z.H. Siddik Bimodal effects of 1R,2R-diaminocyclohexane(trans-diacetato)(dichloro)platinum(IV) on cell cycle checkpoints Clin Cancer Res 7 2001 3629 3639 (Pubitemid 33070004)
10. M.G. Ormerod, R.M. Orr, and J.H. Peacock The role of apoptosis in cell killing by cisplatin: a flow cytometric study Br J Cancer 69 1994 93 100 (Pubitemid 24021828)
11. C.M. Sorenson, and A. Eastman Mechanism of cis- diamminedichloroplatinum(II)-induced cytotoxicity: role of G2 arrest and DNA double-strand breaks Cancer Res 48 1988 4484 4488
12. D.B. Zamble, T. Jacks, and S.J. Lippard p53-Dependent and -independent responses to cisplatin in mouse testicular teratocarcinoma cells Proc Natl Acad Sci U S A 95 1998 6163 6168 (Pubitemid 28248982)
13. D.E. Wilkins, C.E. Ng, and G.P. Raaphorst Cell cycle perturbations in cisplatin-sensitive and resistant human ovarian carcinoma cells following treatment with cisplatin and low dose rate irradiation Cancer Chemother Pharmacol 40 1997 159 166 (Pubitemid 27214595)
14. L.D. Attardi, A. de Vries, and T. Jacks Activation of the p53-dependent G1 checkpoint response in mouse embryo fibroblasts depends on the specific DNA damage inducer Oncogene 23 2004 973 980 (Pubitemid 38250943)
15. M. Koprinarova, P. Markovska, I. Iliev, B. Anachkova, and G. Russev Sodium butyrate enhances the cytotoxic effect of cisplatin by abrogating the cisplatin imposed cell cycle arrest BMC Mol Biol 11 2010 49
16. G. He, Z.H. Siddik, Z. Huang, R. Wang, J. Koomen, and R. Kobayashi Induction of p21 by p53 following DNA damage inhibits both Cdk4 and Cdk2 activities Oncogene 24 2005 2929 2943 (Pubitemid 40675524)
17. G. He, J. Kuang, Z. Huang, J. Koomen, R. Kobayashi, A.R. Khokhar, and Z.H. Siddik Upregulation of p27 and its inhibition of CDK2/cyclin E activity following DNA damage by a novel platinum agent are dependent on the expression of p21 Br J Cancer 95 2006 1514 1524 (Pubitemid 44863354)
18. P.C. Billings, R.J. Davis, B.N. Engelsberg, K.A. Skov, and E.N. Hughes Characterization of high mobility group protein binding to cisplatin-damaged DNA Biochem Biophys Res Commun 188 1992 1286 1294
19. E.N. Hughes, B.N. Engelsberg, and P.C. Billings Purification of nuclear proteins that bind to cisplatin-damaged DNA. Identity with high mobility group proteins 1 and 2 J Biol Chem 267 1992 13520 13527
20. B. Marples, H. Adomat, P.C. Billings, N.P. Farrell, C.J. Koch, and K.A. Skov Recognition of platinum-induced DNA damage by nuclear proteins: screening for mechanisms Anticancer Drug Des 9 1994 389 399 (Pubitemid 24343633)
21. Y. Kido, A.R. Khokhar, S. al Baker, and Z.H. Siddik Modulation of cytotoxicity and cellular pharmacology of 1,2-diaminocyclohexane platinum (IV) complexes mediated by axial and equatorial ligands Cancer Res 53 1993 4567 4572 (Pubitemid 23304381)
22. J.D. Dignam, R.M. Lebovitz, and R.G. Roeder Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei Nucleic Acids Res 11 1983 1475 1489
23. K.A. Lee, A. Bindereif, and M.R. Green A small-scale procedure for preparation of nuclear extracts that support efficient transcription and pre-mRNA splicing Gene Anal Tech 5 1988 22 31
24. Z.H. Siddik, G.S. Hagopian, G. Thai, S. Tomisaki, T. Toyomasu, and A.R. Khokhar Role of p53 in the ability of 1,2-diaminocyclohexane-diacetato-dichloro- Pt(IV) to circumvent cisplatin resistance J Inorg Biochem 77 1999 65 70 (Pubitemid 30089084)
25. W.G. Dunphy The decision to enter mitosis Trends Cell Biol 4 1994 202 207 (Pubitemid 24152417)
26. L.D. Berry, and K.L. Gould Regulation of Cdc2 activity by phosphorylation at T14/Y15 Prog Cell Cycle Res 2 1996 99 105
27. U. Nylen, Q. He, I. Welander, F. Lewin, and S. Skog Cisplatin-induced inhibition of p34cdc2 is abolished by 5-fluorouracil Acta Oncol 37 1998 355 363 (Pubitemid 28384490)
28. J.W. Harper, G.R. Adami, N. Wei, K. Keyomarsi, and S.J. Elledge The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases Cell 75 1993 805 816 (Pubitemid 23346377)
29. J. LaBaer, M.D. Garrett, L.F. Stevenson, J.M. Slingerland, C. Sandhu, and H.S. Chou New functional activities for the p21 family of CDK inhibitors Genes Dev 11 1997 847 862 (Pubitemid 27175292)
30. A.G. Eliopoulos, D.J. Kerr, J. Herod, L. Hodgkins, S. Krajewski, J.C. Reed, and L.S. Young The control of apoptosis and drug resistance in ovarian cancer: influence of p53 and Bcl-2 Oncogene 11 1995 1217 1228
31. P.M. O'Connor, D.K. Ferris, G.A. White, J. Pines, T. Hunter, D.L. Longo, and K.W. Kohn Relationships between cdc2 kinase, DNA cross-linking, and cell cycle perturbations induced by nitrogen mustard Cell Growth Differ 3 1992 43 52
32. H. Nagasawa, C.Y. Li, C.G. Maki, A.C. Imrich, and J.B. Little Relationship between radiation-induced G1 phase arrest and p53 function in human tumor cells Cancer Res 55 1995 1842 1846
33. A. Azuma, P. Huang, A. Matsuda, and W. Plunkett 2′-C-cyano- 2′-deoxy-1-beta-d-arabino-pentofuranosylcytosine: a novel anticancer nucleoside analog that causes both DNA strand breaks and G(2) arrest Mol Pharmacol 59 2001 725 731 (Pubitemid 32279610)
34. J. Agner, J. Falck, J. Lukas, and J. Bartek Differential impact of diverse anticancer chemotherapeutics on the Cdc25A-degradation checkpoint pathway Exp Cell Res 302 2005 162 169 (Pubitemid 39550459)
35. H. Zhao, and H. Piwnica-Worms ATR-mediated checkpoint pathways regulate phosphorylation and activation of human Chk1 Mol Cell Biol 21 2001 4129 4139 (Pubitemid 32565295)
36. G. Damia, L. Filiberti, F. Vikhanskaya, L. Carrassa, Y. Taya, M. D'Incalci, and M. Broggini Cisplatinum and taxol induce different patterns of p53 phosphorylation Neoplasia 3 2001 10 16 (Pubitemid 32201605)
37. T. Waldman, K.W. Kinzler, and B. Vogelstein p21 is necessary for the p53-mediated G1 arrest in human cancer cells Cancer Res 55 1995 5187 5190
38. V. Gottifredi, O. Karni-Schmidt, S.S. Shieh, and C. Prives p53 down-regulates CHK1 through p21 and the retinoblastoma protein Mol Cell Biol 21 2001 1066 1076 (Pubitemid 32114956)
39. K. Lohr, C. Moritz, A. Contente, and M. Dobbelstein p21/CDKN1A mediates negative regulation of transcription by p53 J Biol Chem 278 2003 32507 32516 (Pubitemid 37055688)
40. K. Rother, R. Kirschner, K. Sanger, L. Bohlig, J. Mossner, and K. Engeland p53 downregulates expression of the G1/S cell cycle phosphatase Cdc25A Oncogene 26 2007 1949 1953 (Pubitemid 46474635)
41. A. Vigneron, J. Cherier, B. Barre, E. Gamelin, and O. Coqueret The cell cycle inhibitor p21waf1 binds to the myc and cdc25A promoters upon DNA damage and induces transcriptional repression J Biol Chem 281 2006 34742 34750 (Pubitemid 46036514)
42. G. Iliakis, Y. Wang, J. Guan, and H. Wang DNA damage checkpoint control in cells exposed to ionizing radiation Oncogene 22 2003 5834 5847 (Pubitemid 37176704)
43. W.R. Taylor, and G.R. Stark Regulation of the G2/M transition by p53 Oncogene 20 2001 1803 1815 (Pubitemid 32458690)
44. D. Fink, S. Nebel, S. Aebi, H. Zheng, B. Cenni, and A. Nehme The role of DNA mismatch repair in platinum drug resistance Cancer Res 56 1996 4881 4886 (Pubitemid 26374423)
45. Z.H. Siddik DNA-interactive alkylating agents and antitumour platinum-based drugs M.R. Alison, The cancer handbook 2002 Nature Publishing Group London 1295 1312
46. V. Di Felice, M. Lauricella, M. Giuliano, S. Emanuele, R. Vento, and G. Tesoriere The apoptotic effects of cisplatin and carboplatin in retinoblastoma Y79 cells Int J Oncol 13 1998 225 232 (Pubitemid 28329208)
47. S. Cruet-Hennequart, S. Villalan, A. Kaczmarczyk, E. O'Meara, A.M. Sokol, and M.P. Carty Characterization of the effects of cisplatin and carboplatin on cell cycle progression and DNA damage response activation in DNA polymerase eta-deficient human cells Cell Cycle 8 2009 3039 3050
48. C. Lavarino, S. Pilotti, M. Oggionni, L. Gatti, P. Perego, and G. Bresciani p53 gene status and response to platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma J Clin Oncol 18 2000 3936 3945
49. S.C. Righetti, T.G. Della, S. Pilotti, S. Menard, F. Ottone, and M.I. Colnaghi A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma Cancer Res 56 1996 689 693 (Pubitemid 26055453)
50. J. Reedijk New clues for platinum antitumor chemistry: kinetically controlled metal binding to DNA Proc Natl Acad Sci U S A 100 2003 3611 3616 (Pubitemid 36422584)